Results of a naturalistic longitudinal study of benzodiazepine and SSRI use in the treatment of generalized anxiety disorder and social phobia

Depression and Anxiety

Volumn 22, Issue 2, 2005, Pages 59-67

  Vasile, Russell G ^a   Bruce, Steven E ^b   Goisman, Robert M ^c,d   Pagano, Maria ^b   Keller, Martin B ^b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b BROWN UNIVERSITY   (United States)

^c MASSACHUSETTS MENTAL HEALTH CENTER   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Generalized anxiety disorder; Psychotropic drugs; Social phobia; Treatment guidelines

Indexed keywords

ALPRAZOLAM; BENZODIAZEPINE DERIVATIVE; CLONAZEPAM; DIAZEPAM; FLUOXETINE; LORAZEPAM; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; CLINICAL TRIAL; DRUG EFFECT; FEMALE; FOLLOW UP; GENERALIZED ANXIETY DISORDER; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RATING SCALE; SOCIAL PHOBIA;

ADULT; ANXIETY DISORDERS; BENZODIAZEPINES; DRUG UTILIZATION; FEMALE; FOLLOW-UP STUDIES; GUIDELINE ADHERENCE; HUMANS; LONGITUDINAL STUDIES; MALE; MASSACHUSETTS; OBSERVER VARIATION; PHOBIC DISORDERS; PSYCHIATRIC STATUS RATING SCALES; REPRODUCIBILITY OF RESULTS; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS;

EID: 27744458830     PISSN: 10914269     EISSN: None     Source Type: Journal    
DOI: 10.1002/da.20089     Document Type: Article

References (31)

1. Ballenger JC, Davidson JR, Lecrubier Y, Nutt DJ, Bobes J, Beidel DC, Ono Y, Westenberg HG. 1998. Consensus Statement on social anxiety disorder from the international consensus group on depression and anxiety. J Clin Psychiatry 59(Suppl):54-60.
2. Ballenger JC, Davidson JR, Lecrubier Y, Nutt DJ, Borkovec TD, Rickels K, Stein DJ, Wittchen HU. 2001. Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry 62(Suppl):53-58.
3. Bruce SE, Vasile RG, Goisman RM, Salzman C, Spencer M, Machan JT, Keller MB. 2003. Are benzodiazepines still the medication of choice for patients with panic disorder with or without agoraphobia? Am J Psychiatry 160:1432-1438.
4. Bruce SE, Yonkers K, Otto M, Eisen J, Weisberg R, Shea T, Pagano M, Keller MB. 2005. A 12-year prospective study of generalized anxiety disorder, panic disorder, and social phobia: psychiatric comorbidity as predictors of recovery and recurrence. Am J Psychiatry 162:1179-1187.
5. Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PA, Rubin HR. 1998. Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA 282:1458-1465.
6. Cheeta S, Schifano F, Oyefeso A, Webb L, Ghodse AH. 2004. Antidepressant-related deaths and antidepressant prescriptions in England and Wales, 1998-2000. Br J Psychiatry 184:41-47.
7. Clayton A, Pradko JF, Croft HA, Montano CB, Leadbetter RA, Bolden-Watson C, Bass KI, Donahue RM, Jamerson BD, Metz A. 2002. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 63:357-366.
8. Cowley DS, Ha EH, Roy Byrne PP. 1997. Determinants of pharmacologic treatment failure in panic disorder. J Clin Psychiatry 58:555-561.
9. Dugan E, Cohen SJ. 1998. Improving physicians' implementation of clinical practice guidelines: enhancing primary care practice. In: Shumaker S, Schron EB, Ockene JK, editors. The handbook of health behavior change. New York: Springer Publishing Co. Inc. 607 p.
10. Ferrier B, Woodward CA, Cohen M, Williams AP. 1996. Clinical practice guidelines: new-to-practice family physicians' attitudes. Can Fam Physician 42:463-468.
11. Goisman RM, Rogers MP, Steketee GS, Warshaw MG, Cuneo P, Keller MB. 1993. Utilization of behavioral methods in a multicenter anxiety disorders study. J Clin Psychiatry 54:213-218.
12. Goisman RM, Warshaw MG, Keller MB. 1999. Psychosocial treatment prescriptions for generalized anxiety disorder, panic disorder, and social phobia, 1991-1996. Am J Psychiatry 156:1819-1821.
13. Haddad P. 1998. The SSRI discontinuation syndrome. J Psychopharmacol 12:305-313.
14. Keller M, Lavori P, Friedman B, Neilson E, Endicott J, McDonald-Scott N, Andreasen N. 1987. The longitudinal interval follow-up evaluation: a comprehensive method for assessing outcome in prospective longitudinal studies. Arch Gen Psychiatry 44:540-548.
15. Keller MB, Yonkers KA, Warshaw MG, Pratt LA, Gollan JK, Massion AO, White K, Swartz AR, Reich J, Lavori PW. 1994. Remission and relapse in subjects with panic disorder and panic with agoraphobia: a prospective short interval naturalistic follow-up. J Nerv Ment Dis 182:290-296.
16. Kessler R, McGonagle K, Zhao S, Nelson C, Hughes M, Eshleman S, Wittchen H, Kendler K. 1994. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch Gen Psychiatry 51:8-19.
17. Liebowitz MR, Stein MB, Tancer M, Carpenter D, Oakes R, Pitts CD. 2002. A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in treatment of generalized social anxiety disorder. J Clin Psychiatry 63:66-74.
18. Lomas J, Anderson GM, Domnick-Pierre K, Vayda E, Enkin MW, Hannah WJ. 1989. Do practice guidelines guide practice? The effect of a consensus statement on the practice of physicians. N Engl J Med 321:1306-1311.
19. Mellman T, Miller AL, Weissman EM, Crismon ML, Essock SM, Marder SR. 2001. Evidence-based pharmacologic treatment for people with severe mental illness: a focus on guidelines and algorithms. Psychiatr Serv 52:619-625.
20. Montgomery SA, Mahe V, Haudiquet V, Hackett D. 2002. Effectiveness of venlafaxine, extended release formulation, in the short-term and long-term treatment of generalized anxiety disorder: results of a survival analysis. J Clin Psychopharmacol 22:561-567.
21. Olfson M, Marcus S, Wan G, Geissler E. 2004. National trends in the outpatient treatment of anxiety disorders. J Clin Psychiatry 65:1166-1173.
22. Rickels K, Pollack MH, Sheehan DV, Haskins JT. 2000. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry 157:968-974.
23. Romach M, Busto U, Somer MA, Kaplan, HL, Sellers E. 1995. Clinical aspects of the chronic use of alprazolam and lorazepam. Am J Psychiatry 152:1161-1167.
24. Roy Byrne PP, Sherbourne CD, Craske MG, Stein MB, Katon W, Sullivan G, Means-Christensen A, Bystritsky A. 2003. Moving treatment research from clinical trials to the real world. Psychiatr Serv 54:327-332.
25. Salzman C, Goldenberg I, Bruce SE, Keller MB. 2001. Pharmacologic treatment of anxiety disorders in 1989 versus 1996: results from the Harvard/Brown Anxiety Disorders Research Program. J Clin Psychiatry 62:149-152.
26. SAS Institute I. 1990. SAS Circle, Box 8000, Cary, North Carolina 27512-8000.
27. Shader RI, Greenblatt DJ. 1993. Use of benzodiazepines in anxiety disorders. N Engl J Med 328:1398-1405.
28. Stein MB, Sherbourne C, Craske M, Means-Christensen A, Bystritsky A, Katon W, Sullivan G, Roy-Byrne P. 2004. Quality of care for primary care patients with anxiety disorders. Am J Psychiatry 161:2230-2237.
29. Stein DJ, Versiani M, Hair T, Kumar R. 2002. Efficacy of paroxetine for relapse prevention in social anxiety disorder. Arch Gen Psychiatry 59:1111-1118.
30. Uhlenhuth EH, Baiter MB, Ban TA, Yang K. 1999. International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications: VI. Trends in recommendations for the pharmacotherapy of anxiety disorders, 1992-1997. Depress Anxiety 9:107-116.
31. Warshaw MG, Keller MB, Stout RL. 1994. Reliability and validity of the longitudinal interval follow-up evaluation for assessing outcome of anxiety disorders. J Psychiatr Res 28:531-545.